Search Results
Jul 21, 2026, 09:00 ET A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
cell-therapy-for-diabetes field is drawing serious attention, with Vertex Pharmaceuticals (Nasdaq: VRTX), Eledon Pharmaceuticals (Nasdaq: ELDN), Sernova Biotherapeutics (OTC: SEOVF), and Viking Therapeutics (Nasdaq: VKTX) all advancing programs across the diabetes and metabolic
More news about: American News Group
Jul 08, 2026, 09:00 ET The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
the immune system - two routes to the same prize of durable cell therapy.Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN)Eledon Pharmaceuticals (NASDAQ: ELDN) attacks the transplant-rejection problem from the immune side. Its lead antibody tegoprubart targets the CD40 Ligand pathway
More news about: USA News Group
Apr 06, 2026, 13:10 ET Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
(NASDAQ: VCEL), Sana Biotechnology (NASDAQ: SANA), Lineage Cell Therapeutics (NYSE-A: LCTX), and Eledon Pharmaceuticals (NASDAQ: ELDN).
More news about: USA News Group
Mar 09, 2026, 07:00 ET NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN), a clinical-stage immunology company with a focus on transplant medicine.
More news about: NewcelX Ltd.
Dec 31, 2025, 08:07 ET The End of Shots? 5 Biotech Stocks Rethinking Diabetes
strategic roadmaps of Avant Technologies, Inc. (OTCQB: AVAI), Novo Nordisk A/S (NYSE: NVO), Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), Viking Therapeutics, Inc. (NASDAQ: VKTX), and Tandem Diabetes Care, Inc. (NASDAQ: TNDM).
More news about: USA News Group